Novartis to present cancer drug data at ASH and SABCS 2014

Novartis has announced that it will be presenting more than 250 abstracts at a pair of oncology-focused conferences taking place in the coming weeks.

The company will attend the American Society of Hematology (ASH) annual meeting from December 6th to 9th, followed by the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from December 9th to 13th, to discuss their latest advances in blood and breast cancer research.

Presentations will highlight cell and gene therapy research advances, as well as approaches to targeting multiple pathways at once to treat various cancers, plus established safety and efficacy with long-term data from the haematology portfolio.

New findings on compounds such as CTL019, Jakavi, Exjade and Afinitor will all be featured during the events.

Dr Alessandro Riva, global head of oncology development and medical affairs at Novartis, said: "With our robust cancer pipeline, we look forward to many more years of meaningful progress for people living with cancer."

This comes after the firm presented new rheumatology drug data at the American College of Rheumatology Congress last month.